SCHEMBL5465471

SCHEMBL5465471

COc1ccc(/C=C2\SC(=O)N(Cc3ccc(Cl)c(Cl)c3)C2=O)cc1N

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 9/20 0.58
▸ PTPN1 P18031 5/20 0.56
▸ ACP1 P24666 4/20 0.56
▸ PTPN2 P17706 4/20 0.54
▸ HPGD P15428 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ GAA P10253 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ DNMT1 P26358 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ DUSP3 P51452 1/20 0.51
▸ MCL1 Q07820 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ PPARG P37231 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465473 1.00 ENPP2 (0.58) ENPP2PTPN1ACP1PTPN2HPGD
SCHEMBL5468461 0.90 PTPN1 (0.63) ENPP2PTPN1ACP1PTPN2HPGD
SCHEMBL5468456 0.90 PTPN1 (0.63) ENPP2PTPN1ACP1PTPN2HPGD
SCHEMBL5474318 0.88 ENPP2 (0.60) ENPP2PTPN1ACP1PTPN2HPGD
SCHEMBL5474321 0.88 ENPP2 (0.60) ENPP2PTPN1ACP1PTPN2HPGD
SCHEMBL5470270 0.85 ENPP2 (0.61) ENPP2PTPN1ACP1PTPN2ALDH1A1
SCHEMBL5470266 0.85 ENPP2 (0.61) ENPP2PTPN1ACP1PTPN2ALDH1A1
SCHEMBL5464244 0.85 ENPP2 (0.57) ENPP2PTPN1ACP1PTPN2HPGD
SCHEMBL5463956 0.85 ENPP2 (0.57) ENPP2PTPN1ACP1PTPN2HPGD
SCHEMBL5463953 0.85 ENPP2 (0.57) ENPP2PTPN1ACP1PTPN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 ENPP2 1911/4885PTPN1 3264/4885ACP1 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback